share_log

Eli Lilly and Co | 8-K: Eli Lilly Announces Anat - Ashkenazi to Resign as Executive Vice President and Chief Financial Officer

Eli Lilly and Co | 8-K: Eli Lilly Announces Anat - Ashkenazi to Resign as Executive Vice President and Chief Financial Officer

礼来 | 8-K:礼来宣布Anat - Ashkenazi将辞去执行副总裁兼首席财务官一职
美股sec公告 ·  07/10 08:44
Moomoo AI 已提取核心信息
Eli Lilly and Company reported a significant change in its executive team with the resignation of Anat Ashkenazi as the executive vice president and chief financial officer, effective June 5, 2024. Ashkenazi has decided to leave the pharmaceutical industry to pursue a different career path. Following her departure, Gordon Brooks, who has been with Eli Lilly for 29 years and currently serves as the group vice president, controller and corporate strategy, will take over as the interim chief financial officer starting July 15, 2024. Brooks has a diverse background within the company's finance organization, including roles as senior vice president, chief procurement officer, and general auditor. The company has confirmed that there are no familial or transactional relationships influencing Brooks' appointment. Ashkenazi will assist with the transition until the end of July 2024.
Eli Lilly and Company reported a significant change in its executive team with the resignation of Anat Ashkenazi as the executive vice president and chief financial officer, effective June 5, 2024. Ashkenazi has decided to leave the pharmaceutical industry to pursue a different career path. Following her departure, Gordon Brooks, who has been with Eli Lilly for 29 years and currently serves as the group vice president, controller and corporate strategy, will take over as the interim chief financial officer starting July 15, 2024. Brooks has a diverse background within the company's finance organization, including roles as senior vice president, chief procurement officer, and general auditor. The company has confirmed that there are no familial or transactional relationships influencing Brooks' appointment. Ashkenazi will assist with the transition until the end of July 2024.
艾黎利(Lilly)公司报告其高管团队出现重大变动,Anat Ashkenazi已辞去执行副总裁兼首席财务官职位,将于2024年6月5日生效。 Ashkenazi决定离开药品行业,追求不同的职业道路。在她离职后,Gordon Brooks将接替她的工作,从2024年7月15日开始担任临时首席财务官。 Brooks在Eli Lilly工作了29年,目前担任集团副总裁、人形机器人-电机控制器和公司策略。在公司金融组织中,Brooks拥有丰富的背景,包括资深副总裁、首席采购官和常务审计。该公司已经确认没有任何家庭或交易关系影响Brooks的任命。Ashkenazi将协助过渡,直到2024年7月底。
艾黎利(Lilly)公司报告其高管团队出现重大变动,Anat Ashkenazi已辞去执行副总裁兼首席财务官职位,将于2024年6月5日生效。 Ashkenazi决定离开药品行业,追求不同的职业道路。在她离职后,Gordon Brooks将接替她的工作,从2024年7月15日开始担任临时首席财务官。 Brooks在Eli Lilly工作了29年,目前担任集团副总裁、人形机器人-电机控制器和公司策略。在公司金融组织中,Brooks拥有丰富的背景,包括资深副总裁、首席采购官和常务审计。该公司已经确认没有任何家庭或交易关系影响Brooks的任命。Ashkenazi将协助过渡,直到2024年7月底。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息